Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Tuesday, May 26, 2026 1 min read
Key Takeaway: Arcturus Therapeutics Holdings Inc. has announced its participation in the 2026 Jefferies Global Healthcare Conference. The company, known for its focus on messenger RNA medicines, aims to showcase its developments in therapeutics for liver and respiratory rare diseases. This presentation reflects Arcturus's commitment to engaging with the healthcare investment community.
Price reaction · baseline $7.21 (2026-05-26 close) · hit after-hours · clean, no other ARCT news in the window
day 0 close
+6.2%
day 1 · peak
+9.8%
day 3
+7.8%
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Arcturus Therapeutics is actively engaging with investors.
The presentation highlights the company's focus on innovative mRNA medicines.
Participation in a notable healthcare conference indicates growth potential.
Full Press Release Details
SAN DIEGO –(BUSINESS WIRE)–May 26, 2026– Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following
The post Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference appeared first on Arcturus Therapeutics .
Frequently Asked Questions
What will Arcturus present at the Jefferies Conference?
Arcturus will present its developments in messenger RNA medicines.
When is the Jefferies Global Healthcare Conference?
The conference is scheduled for 2026.
What focus areas does Arcturus specialize in?
Arcturus specializes in liver and respiratory rare disease therapeutics.